Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday said it has secured an ...

It’s a good place to develop, with generous government incentives, including a Research & Development (R&D) rebate. There are ...

She previously served as Chief Executive Officer at Harpoon Therapeutics until the company's acquisition by Merck in early 2024. In addition to Ms. Eastland's appointment, Ingmar Bruns, M.D., has been ...

Winners received prestigious award in recognition of latest innovations in advancement in life sciences ...

Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end. Encouraging clinical responses observed in ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...

Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical ...

On Friday, North Penn Vol. Fire Co. in North Wales Borough recognized 60 years since the death of one of their own in the ...

Merck & Co. is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Merck lowered guidance for 2024 adjusted earnings per share to the ...